[Hinews] From September 15 to 18, 2025, GC Genome, a South Korean leader in genomic diagnostics, held a series of seminars in Bahrain and Saudi Arabia to promote its innovative multi-cancer early detection service, ai-CANCERCH. The events, which focused on forging strategic partnerships with key regional institutions, marked a significant step in the company’s expansion into the rapidly growing Middle Eastern healthcare market.

In Bahrain, GC Genome collaborated with BioLab, a prominent local diagnostics provider, to showcase ai-CANCERCH’s capabilities. The seminar drew interest from representatives of major Bahraini hospitals, who expressed enthusiasm for the technology’s potential to enhance early cancer detection. Notably, a major government hospital in Bahrain invited GC Genome to present at the 2025 Manama Health Congress & Expo in December, signaling strong local support for the initiative.

GC Genome introduces its multi-cancer early detection service, ai-CANCERCH, during a seminar in the Middle East. (Photo provided by GC Genome)
GC Genome introduces its multi-cancer early detection service, ai-CANCERCH, during a seminar in the Middle East. (Photo provided by GC Genome)


In Saudi Arabia, GC Genome partnered with Advanced Cell Laboratory, a CAP-accredited molecular diagnostics institution, and Genelab, which operates the country’s largest genomics and data center and plays a key role in national health projects. Discussions during the seminars centered on transferring advanced analytical technologies and exploring deeper collaboration to integrate ai-CANCERCH into regional healthcare systems.

Ki Chang-seok, CEO of GC Genome, highlighted the region’s potential, stating, “The Middle East’s health screening market is projected to grow from $21.8 billion in 2025 to $43.2 billion by 2031, with an annual growth rate of 11.5%.” He added, “These partnerships strengthen our regional network and lay the foundation for the widespread adoption of ai-CANCERCH across the Middle East.”
The seminars formalized cooperative agreements with BioLab, Advanced Cell Laboratory, and Genelab, positioning GC Genome to capitalize on the increasing demand for advanced diagnostic solutions in the region.

키워드

#GC지놈#아이캔서치
저작권자 © Hinews 무단전재 및 재배포 금지
ad